- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04228692
Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery
Evaluation of the Benefits of Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery
Symptomatic endometriosis can be responsible for urinary problems as well as symptoms of clinical bladder hyperactivity and/or symptoms of bladder pain before or during miction that can persist after bladder voiding. Whereas urinary problems can predate surgery due to the endometrial lesions themselves, the surgery can also have functional consequences for urinary function, specifically when there is trauma (incisions, per-operative coagulation) to the inferior hypogastric nerve fibers and/or to the hypogastric plexus.
The incidence of post-surgery urinary symptoms could be as high as 30%. The incidence of voiding problems and specifically of non-obstructive voiding dysfunction can be observed in 17,5% of cases of patients 1-month post-surgery for deep colorectal endometriosis, and persists in 4,8% of women after 12 months.
The gold standard for treatment of voiding problems consists of self-catheterization, as is the case for all non-obstructive voiding dysfunction symptoms. This procedure considerably impacts quality of life. The proper and complete voiding of the bladder remains essential in order to avoid recurring urinary tract infections and pelvic static disorder.
In the case of persistent dysuria, the use of self-catheterization is necessary in 21% of patients after surgery for deep endometriosis, for an average duration of 85 days. To date, few studies have explored the management of post-operative urinary complications after surgery for deep endometriosis. Pharmaceutical alternatives (alpha-blockers, anticholinergics, benzodiazepines) have not proven effective and sometimes cause side effects. However promising alternative treatments are being developed, specifically the neuromodulation of the sacral root. This procedure has been shown effective in the treatment of non-obstructive voiding dysfunction; however, it remains an invasive treatment that has its load of complications and undesirable side-effects. A recent study reports favorable results for the use of sacral neuromodulation in the case of persistent incomplete voiding following surgery for deep colorectal endometriosis. Some studies have also suggested that percutaneous posterior tibial nerve stimulation (PTN) could also be a treatment alternative. The advantage of this procedure is that it is non-invasive and less constraining. No study has yet evaluated whether PTN could also be used to treat patients with persistent voiding dysfunction following surgery for deep endometriosis.
Our study, conducted in the gynecologic department of Croix ROUSSE Hospital, Lyon (France), evaluates PTN as a new treatment option for post-operative voiding dysfunction in women who suffer from deep endometriosis. Our aim is to prove that the use of PTN can reduce the duration of self-catheterization by 50% when compared to self-catheterization only.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sophie WAREMBOURG, Dr
- Phone Number: +33 4.72.07.19.36
- Email: sophie.warembourg@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69004
- Hopital de la Croix Rousse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who are eligible for the French public healthcare system
- Patients who have given their consent for this research
Exclusion Criteria:
- Patients with cognitive, psychiatric or motor disturbances, that do not allow for independent use of the device
- Patients who do not speak French
- Patients who have had a surgery (bladder or ureters) for endometriosis or any other reason.
- Patients who were participating in another ongoing study, or within the exclusion time stipulated by another study (at the discretion of the investigator)
- Patients unable to give their consent (protected by law: under guardianship / trusteeship)
- Patients who are taking a pharmaceutical treatment for urological problem (anticholinergics, alpha-blockers, prostaglandin)
- Pregnant or breastfeeding women
- Patients with a pacemaker
- Patients with dermatological problem in the area where the device's electrodes have to be installed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Self-catheterization only
Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary
|
Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
|
Experimental: Posterior tibial nerve stimulation + self-catheterization
Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization. Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary. |
Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary. Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of 50% of total duration of self-catheterization in the self-catheterization + PTN group
Time Frame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
Comparison of total numbers of days of self-catheterization between the 2 groups
|
From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of self-catheterizations per day
Time Frame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
Patients will complete a voiding calendar as long as self-catheterization is required
|
From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
Post voiding residual urine volume (PVR)
Time Frame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
Patients will complete a voiding calendar as long as self-catheterization is required
|
From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
number of PVR> 50% of spontaneous miction
Time Frame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
Patients will complete a voiding calendar as long as self-catheterization is required
|
From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
side effects of PTN
Time Frame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
sensation of small electrical discharges, skin reactions next to the electrodes will be notified by patients
|
From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
number of sessions of PTN per week
Time Frame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
|
duration of each session of PTN
Time Frame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
From the day of surgery to the end of self-catheterization or until a maximum of 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sophie WAREMBOURG, Dr, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL19_0686
- 2019-A02583-54 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Semmelweis UniversityUniversity of PecsNot yet recruitingEndometriosis | Endometriosis Ovary | Endometriosis Rectovaginal Septum
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
Clinical Trials on Self-catheterization only
-
Shirley Ryan AbilityLabCompleted
-
Women and Infants Hospital of Rhode IslandAmerican Urogynecologic Society; American Association of Gynecologic LaparoscopistsActive, not recruitingVoiding Disorders | Urinary Retention PostoperativeUnited States
-
University of British ColumbiaConvaTec Inc.; Vancouver Coastal Health; International Collaboration on Repair...Not yet recruitingSpinal Cord Injuries | Anxiety State | Urinary Bladder, Neurogenic | Catheter Complications | Autonomic DysreflexiaCanada
-
US Department of Veterans AffairsCompleted
-
Hospital Clínico La FloridaCompleted
-
Norwegian University of Science and TechnologyThe Research Council of NorwayCompletedHeart Failure | Stroke | Chronic Obstructive Pulmonary DiseaseNorway
-
Centre Leon BerardInstitut d'Hématologie et d'Oncologie Pédiatrique; Fondation La Roche PosayNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric
-
Northumbria UniversityNewcastle University; Versus Arthritis; Teesside UniversityUnknownSjogren's SyndromeUnited Kingdom
-
Andrei KrassioukovUniversity of British Columbia; Coloplast A/S; Vancouver Coastal Health; International...CompletedSpinal Cord Injuries | Neurogenic Lower Urinary Tract DysfunctionCanada
-
Ekaterina PogrebtsovaCompletedMental Health Wellness 1